Sales of weight loss drugs have been light, and the Vivus drug Qsymia is no exception. Facing declining revenue as well as a looming mountain of debt, Vivus has been casting about for a new strategy. It looks like it’s found one.

Campbell, CA-based Vivus (NASDAQ: VVUS) has agreed to pay $135 million for the rights to sell a digestion drug, pancrelipase (Pancreaze), in the U.S. and Canada.